Richard Fedorak

CAG interactive lecture series: a Web-based learning program.

Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta.

A model for partnership and research between the CAG and sponsors.

Normal Breast Milk Limits the Development of Colitis in IL-10-Deficient Mice.

Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease.

Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs.

The frequency of vitamin D deficiency in adults with Crohn's disease.

Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.

The 1993 Canadian Association of Gastroenterology Strategic Plan: excellence in achievement.

Infliximab maintenance therapy for fistulizing Crohn's disease.

Endoscopic perforation rates at a Canadian university teaching hospital.

The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting.

Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease.

Probiotics and the management of inflammatory bowel disease.

Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.

Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide.

Is it time to re-classify Crohn's disease?

Probiotics and prebiotics in gastrointestinal disorders.

Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.

Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events.

Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial.

Association with selected bacteria does not cause enterocolitis in IL-10 gene-deficient mice despite a systemic immune response.

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.

Postoperative Crohn's disease.

The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics.

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.

Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases.

Probiotics in the management of inflammatory bowel disease.

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Probiotics in the treatment of inflammatory bowel disease.

Recommendations for probiotic use.

Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury.

Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial.

The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients.

The epidemiology of inflammatory bowel disease in Canada: a population-based study.

A defect in epithelial barrier integrity is not required for a systemic response to bacterial antigens or intestinal injury in T cell receptor-alpha gene-deficient mice.

The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease.

Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial.

Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse.

Vertebral fractures and role of low bone mineral density in Crohn's disease.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age.

CD4+CD25+ regulatory T cells have divergent effects on intestinal inflammation in IL-10 gene-deficient mice.

The role of probiotics in management of irritable bowel syndrome.

Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent?

Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.

Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis.

Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial.

Exercise and inflammatory bowel disease.

Recommendations for probiotic use--2008.

Probiotics in the treatment of human inflammatory bowel diseases: update 2008.

Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice.

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

Understanding why probiotic therapies can be effective in treating IBD.

Are there differences in type, dosage, and method of administration for the systemic steroids in IBD treatment?

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

Bacterial overgrowth and inflammation of small intestine after carboxymethylcellulose ingestion in genetically susceptible mice.

Helicobacter pylori infection in Canada's arctic: searching for the solutions.

Early experience with unsedated ultrathin 4.9 mm transnasal gastroscopy: a pilot study.

Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.

Gastric intramural hematoma: a case report and literature review.

Does smoking reduce infliximab's effectiveness against Crohn's disease?

Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort.

Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD.

Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease.

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.

Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile.

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.

Naturally occurring glycoalkaloids in potatoes aggravate intestinal inflammation in two mouse models of inflammatory bowel disease.

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.

A randomized trial of topical anesthesia comparing lidocaine versus lidocaine plus xylometazoline for unsedated transnasal upper gastrointestinal endoscopy.

Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact.

Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study.

Neonatal exposure to fecal antigens reduces intestinal inflammation.

Metabolomics and detection of colorectal cancer in humans: a systematic review.

Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.

Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease.

Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: Incidence, prevalence, and direct and indirect economic impact.

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients.

Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters.

Probiotics in the management of ulcerative colitis.

Prevalence and Outcome of Upper Gastrointestinal Bleeding Post-coronary Artery Bypass Graft.

Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field.

Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.

Oropharyngeal Crohn's disease.

Intravenous injection of endogenous microbial components abrogates DSS-induced colitis.

Health care resource use and costs in Crohn's disease before and after infliximab therapy.

Probiotic Therapies for IBD.

A randomized controlled trial of four precolonoscopy bowel cleansing regimens.

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.

Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.

Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis.

Small bowel fibrosis and systemic inflammatory response after ileocolonic anastomosis in IL-10 null mice.

Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact.

Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy.

Patients with inflammatory bowel disease exhibit dysregulated responses to microbial DNA.

World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011.

The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer.

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.

Canadian Digestive Health Foundation Public Impact Series 4: celiac disease in Canada. Incidence, prevalence, and direct and indirect economic impact.

Patients undergoing colorectal cancer screening underestimate their cancer risk and delay presentation for screening.

Canadian Digestive Health Foundation Public Impact Series 5: Pancreatitis in Canada. Incidence, prevalence, and direct and indirect economic impact.

Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.

Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.

Development and validation of an administrative case definition for inflammatory bowel diseases.

Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease.

Epithelial gaps in a rodent model of inflammatory bowel disease: a quantitative validation study.

Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease.

Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos).

Celiac disease in children with inflammatory bowel disease: a prospective cohort study.

Epithelial cell extrusion leads to breaches in the intestinal epithelium.

Environment and the inflammatory bowel diseases.

Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.

Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.

Prospective Study of the Quality of Colonoscopies Performed by Primary Care Physicians: The Alberta Primary Care Endoscopy (APC-Endo) Study.

Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Phenotypic features of Crohn's disease associated with failure of medical treatment.

Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

A machine-learned predictor of colonic polyps based on urinary metabolomics.

Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns.

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.

Distance management of inflammatory bowel disease: systematic review and meta-analysis.

Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps.

Real-life Treatment Paradigms Show Infliximab Is Cost-effective for Management of Ulcerative Colitis.

Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review.

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study.

HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants.

Response to letter to the editor.